Brief: FDA Clears Cytodyn's Phase 2 Randomized Trial To Treat Mild-To-Moderately Ill Coronavirus Patients
31/03/2020 12:16
March 31 (Reuters) - Cytodyn Inc CYDY.PK :
* FDA CLEARS CYTODYN’S PHASE 2 RANDOMIZED TRIAL TO TREAT
MILD-TO-MODERATELY ILL CORONAVIRUS PATIENTS WITH LERONLIMAB;
ENROLLMENT TO BEGIN IMMEDIATELY
Source text for Eikon: ID:nGNX4nyrF1
Further company coverage: CYDY.PK
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer